secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0000950170-24-116853
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics PRT3789 Phase 1 interim data: 4 PRs; DAC program preclinical proof-of-concept
--------------------------------------------------------------------------------

- Interim Phase 1 results: 4 confirmed partial responses (2 esophageal, 2 NSCLC) out of 26 evaluable SMARCA4 loss-of-function patients.
- PRT3789 generally well-tolerated; no dose-limiting toxicities or drug-related SAEs; higher doses (≥212 mg) show deeper SMARCA2 degradation.
- Combination with docetaxel shows acceptable safety profile; preclinical data show synergy with chemo in SMARCA4-mutant NSCLC models.
- First preclinical proof-of-concept for SMARCA2/4 dual degrader antibody conjugates (DACs): anti-PSMA DACs show efficacy and tolerability in xenograft models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/0000950170-24-116853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024116853/prld-20241024.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer